Question explored with the scientific record
Menopsuse trestment over 61
The short version: the evidence retrieved does not answer the question "menopause treatment over 61" at all. It is a collection of studies on symptoms, mechanisms, and specific treatments in general menopausal populations, not a single trial in women over 61.
The evidence covers nutraceuticals for hot flushes [1], estrogen's effect on macrophages [2], global symptom prevalence [3], electrolyte changes with estrogen [4], migraine management [5], osteoporosis treatment [6], hormone therapy after cervical cancer [7], and exercise for vasomotor symptoms [8]. None of these studies restrict their population to women over 61. The osteoporosis study [6] reports a mean age of 66.2, but that is an average, not a trial designed for or limited to that age group. The cervical cancer study [7] included women with a mean age likely younger than 61 given 73.4% were postmenopausal and 80% had stage IIIB cancer.
This is a gap, not an answer. The question asks about treatment specifically for women over 61, an age where risks from hormone therapy shift (higher stroke, breast cancer, and clot risks) and where non-hormonal options matter more. The evidence here does not address that age-specific risk-benefit calculation. No study compared outcomes in women over 61 against a placebo or against younger women. No long-term safety data for this age group appears in the retrieved records.
My call: the evidence does not support any specific treatment recommendation for menopause over 61. Confidence: not clear — the question was not studied in the retrieved evidence.
Sources examined 8
-
Another multibotanical for vasomotor symptoms
The study evaluates the effectiveness of a nutraceutical treatment for vasomotor symptoms (VMS) in postmenopausal women, demonstrating a modest reduction in symptoms compared to placebo.
DOI: 10.1097/gme.0b013e3181d2deac -
Alternative Activation of Human Macrophages Is Rescued by Estrogen Treatment In Vitro and Impaired by Menopausal Status
The study shows that 17β-estradiol attenuates proinflammatory signaling and preserves alternative activation in human macrophages in vitro, while menopausal estrogen loss impairs M2 polarization ex vivo, shifting the balance toward M1 and potentially influencing cardiovascular r…
DOI: 10.1210/jc.2014-2751 -
Prevalence of hot flushes and night sweats around the world: a systematic review
A global systematic review synthesizing the prevalence of hot flushes and night sweats among menopausal women across cultures, highlighting substantial cross-cultural variation by menopausal stage and suggesting that reporting is influenced by ethnicity, attitudes toward menopau…
DOI: 10.1080/13697130601181486 -
Plasma electrolyte concentrations in women and the effects of oestrogen administration
This study investigates age-related changes in plasma electrolyte concentrations and urinary excretion in pre-menopausal and post-menopausal women, revealing significant alterations at menopause that are reversible with estrogen treatment.
DOI: 10.1016/0378-5122(82)90055-X -
Menstrual and perimenopausal migraine: A narrative review
This narrative review synthesizes how menstrual and perimenopausal hormonal changes influence migraine, detailing its diagnosis, pathophysiology (notably estrogen withdrawal), prevalence across the menopausal transition, and management options including acute treatment, prophyla…
DOI: 10.1016/j.maturitas.2020.07.005 -
Management of osteoporosis and associated quality of life in post menopausal women
This observational, cross-sectional study evaluates the characteristics, treatment regimens, and quality of life impacts for post-menopausal women diagnosed with osteoporosis in France, revealing significant associations between treatment choices and various patient and physicia…
DOI: 10.1186/1471-2474-12-7 -
Ultrasound assessment of the bone quality of postmenopausal nigerian women
This study evaluated the effect of continuous hormone replacement therapy on menopausal symptoms and urological complaints after treatment for cervical cancer, reporting improvements in menopausal symptoms and cystometry findings with acceptable safety in 124 enrolled patients (…
DOI: 10.1016/s0020-7292(00)82057-3 -
The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial
This randomized controlled trial investigates the effectiveness of exercise as a treatment for vasomotor menopausal symptoms, finding that exercise does not significantly reduce the frequency of hot flushes or night sweats compared to a control group.
DOI: 10.1111/1471-0528.13193